• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

51.11 -0.06 (-0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
December 03, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 21, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
November 12, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Third Quarter 2025 Financial Results
November 04, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 21, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
August 27, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Second Quarter 2025 Financial Results
August 05, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
July 31, 2025
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to... 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 28, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
July 22, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
June 16, 2025
From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.
Via GlobeNewswire
News headline image
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
May 29, 2025
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
May 28, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
May 28, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
May 20, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces First Quarter 2025 Financial Results
May 06, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
April 23, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in Two Upcoming Investor Conferences
March 04, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
February 27, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
February 18, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
February 04, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
January 27, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
November 13, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Third Quarter 2024 Financial Results
November 04, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap